The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.
Zhang G, Guo D, Dash PK, Araínga M, Wiederin JL, Haverland NA, Knibbe-Hollinger J, Martinez-Skinner A, Ciborowski P, Goodfellow VS, Wysocki TA, Wysocki BJ, Poluektova LY, Liu XM, McMillan JM, Gorantla S, Gelbard HA, Gendelman HE.
Zhang G, et al. Among authors: goodfellow vs.
Nanomedicine. 2016 Jan;12(1):109-22. doi: 10.1016/j.nano.2015.09.009. Epub 2015 Oct 22.
Nanomedicine. 2016.
PMID: 26472049
Free PMC article.